期刊文献+

肿瘤发生过程中表观遗传学机制-DNA甲基化的研究进展 被引量:6

Propress of epigenetics mechanism during tumor development---DNA methylation
下载PDF
导出
摘要 表观遗传学是指在不改变DNA序列的前提下,通过化学修饰的作用影响基因的表达,从而改变细胞乃至个体表型的可遗传性基因调节方式。 DNA甲基化是表观遗传学中研究的热点领域之一。近年来,大量研究表明重复序列、特定基因和CpG岛甲基化修饰异常以及印记丢失的发生都与肿瘤的发生发展密切相关。随着甲基化检测手段的不断进步,人们对基因组的甲基化模式有了更加全面的了解。在基因组中发现的异常甲基化位点作为甲基化标志物,可应用于疾病的诊断、治疗及预后评估。并且针对甲基化修饰异常所导致的癌症发生,应用去甲基化药物已在临床治疗中取得良好疗效。 As a heritable regulation , epigenetics can regulate gene expression by other ways without changing the DNA sequence ,and change cell or individual phenotypes .DNA methylation is an issue in the field of epigenetics research.Recently,many studies have been demonstrated that the methylation of repetitive DNA ,spe-cific gene and CpG island and loss of imprinting play an important role in tumor occurrence .As the development of technological approaches to DNA methylation ,we have a more comprehensive understanding on methylation pat-terns.As specific markers,abnormal methylation sites in the genome can be used in the diagnosis ,treatment and prognosis predictor of disease .For tumor development caused by DNA methylation ,the application of demethylat-ing drugs have achieved good effect in clinical treatment .
出处 《实用肿瘤学杂志》 CAS 2015年第2期173-177,共5页 Practical Oncology Journal
基金 国家自然科学基金(81172498) 2.哈尔滨医科大学附属肿瘤医院院内启动基金(JJZ2010-04) 3.哈尔滨医科大学“伍连德”青年基金(WLD-QNlll8) 4.哈尔滨医科大学“中俄”合作医学转化基金(CR201402)
关键词 DNA甲基化 肿瘤 机制 检测 临床应用 DNA methylation Tumor Mechanism Detecting technology Clinical applications
  • 相关文献

参考文献25

  • 1Goll MG, Kirpekar F, Maggert KA, et al. Methylation of tR- NAAsp by the DNA methyhransferase homolog Dnmt2 [ J ]. Science,2006,311 (5759) :395 - 398.
  • 2Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyhransferase gene results in embryonic lethality [ J ]. Cell, 1992,69 (6) :915 - 926.
  • 3Matzke MA, Mette MF, Aufsatz W, et al. Host defenses to parasitic sequences and the evolution of epigenetic control mechanisms [ J ]. Genetic a, 1999,107 ( 1 - 3 ) :271 - 287.
  • 4Feinberg AP, Tycko B. The history of cancer epigenetics [ J ]. Nat Rev Cancer, 2004,4 (2) : 143 - 153.
  • 5De Smet C, Lurquin C, Lethe B, et al. DNA methylation is the primary silencing mechanism for a set of germ line - and tumor - specific genes with a CpG - rich promoter [ J ]. Mol Cell Bio1,1999,19( 11 ) :7327 -7335.
  • 6Nakamura N ,Takenaga K. Hypomethylation of the metastasis - associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines [ J ]. Clin Exp Metas- tasis, 1998,16 ( 5 ) :471 - 479.
  • 7Akiyama Y, Maesawa C, Ogasawara S, et al. Cell - type - specific repression of the maspin gene is disrupted frequent- ly by demethylation at the promoter region in gastric intesti- nal metaplasia and cancer cells[J]. Am J Pathol,2003,163 (5) :1911 -1919.
  • 8Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein gamma gene CpG island promotes its aber- rant expression in breast carcinoma and ovarian carcinoma [ J ]. Cancer Res,2003,63 (3) :664 - 673.
  • 9Song F, Smith JF, Kimura MT, et al. Association of tissue - specific differentially methylated regions(TDMs)with differ- ential gene expression[ J]. Proc Nail Acad Sci U S A ,2005, 102(9) :3336 -3341.
  • 10Issa JP. CpG island methylator phenotype in cancer [ J ]. Nat Rev Cancer, 2004,4 ( 12 ) : 988 - 993.

同被引文献40

  • 1陆嵘,房静远.表观遗传修饰与肿瘤[J].生命科学,2006,18(1):10-14. 被引量:29
  • 2钟济华,陈芳源,王海嵘,黄洪晖,钟华,韩洁英,宣正华,欧阳仁荣.CAG方案对急性髓系白血病细胞作用机制的研究[J].中华血液学杂志,2006,27(7):492-494. 被引量:25
  • 3蒋定锋,潘娟娟,赵耐青.差异表达基因筛选方法的比较[J].中国卫生统计,2006,23(5):417-420. 被引量:7
  • 4张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1.
  • 5腾丽娟,张长松,李克.营养与肿瘤表观遗传学关系的研究进展——DNA甲基化机制[J].医学研究生学报,2008,21(1):95-97. 被引量:12
  • 6Oran B,Weisdorf DJ.Survival for olde rpatients with acute myeloid leukemia:apopulation-based study[J].Haematologica,2012,97(12):1916-1924.
  • 7Lubbert M,Ruter BH,Claus R,et al.A multicenter phaseⅡtrail of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy[J].Haematologica,2012,97(3):393-401.
  • 8Richie EK,Feldman EJ,Chrietos PJ,et al.Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia[J].Leuk Lymphoma,2013,54(9):2003-2007.
  • 9Bhatnagar B,Duong VH,Gourdin TS,et al.Ten-day decitabine as inital therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy[J].Leuk Lymphoma,2014,55(7):1533-1537.
  • 10Ravandi F,Issa JP,Garcia-Manero G,et al.Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-rise myelodysplastic syndrome and chromosome 5and 7abnormalities[J].Cancer,2009,115(24):5746-5751.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部